Considering the concerns related to potential endocrine-disrupting properties of “Salicylic Acid” the European Commission has asked the Scientific Committee to assess its safety in cosmetic products. On 3 February 2022, this mandate has been accepted by the SCCS and the Committee has nine months to deliver its Opinion.

This content is only available to Premium Members.

Get access to all our Premium content and services.
Start your Free Trial or Discover our plans.

Already a Premium member? Sign In

Don`t copy text!